Over 235 companies worldwide claim to offer contract manufacturing services for various types of biopharmaceutical drug / therapy products
Owing to the ever-increasing number ofstart-ups that are involved in R&D of novel biologics, there is an enormousopportunity for the CMOs in this domain. It is worth emphasizing that, since2000, more than 115 new CMOs have been established in order to serve to thegrowing demand for novel biologics that have specific manufacturingrequirements. The contemporary contract services market features a mix of largeand small-sized CMOs and is characterized by multiple mergers and acquisitionsas stakeholders strive to broaden their respective service portfolios. This hasenabled several CMOs to offer end-to-end services, ranging from drugdevelopment, including preliminary R&D, preclinical and clinical trials, tocommercial scale production and regulatory filings
To order this 750+page report, which features 200+ figures and 250+ tables, please visit this link
The USD 13.9 billion(by 2030) financial opportunity within the biopharmaceutical manufacturing markethas been analyzed across the following segments:
§ Commonly OutsourcedBusiness Operations
§ Active PharmaceuticalIngredients (API)
§ Finished Dosage Formulations(FDF)
§ Types of ExpressionSystem
§ Mammalian
§ Microbial
§ Others
§ Company Size
§ Small
§ Mid-Sized
§ Large and Very Large
§ Scale of Operation
§ Preclinical
§ Clinical
§ Commercial
§ Key GeographicalRegion
§ North America
§ Europe
§ Asia-Pacific
§ Rest of theWorld
The BiopharmaContract Manufacturing Market (3rd Edition), 2019-2030. report features thefollowing companies, which we identified to be key players in this domain:
§ 3P Biopharmaceuticals
§ Abzena
§ Albany Molecular Research
§ BioVectra
§ BioXcellence (Boehringer Ingelheim)
§ Celonic
§ Charles River Laboratories
§ ChemPartner
§ Cobra Biologics
§ CordenPharma
§ Cytovance Biologics
§ GE Healthcare
§ Goodwin Biotechnology
§ Grand River Aseptic Manufacturing
§ IDT Biologika
§ KBI BioPharma
§ Kemwell Biopharma
§ LFB Biomanufacturing
§ Meridian Life Science
§ Patheon
§ Pfizer CentreOne
§ PX'Therapeutics
§ Samsung BioLogics
§ Sanofi, CEPiA
§ Thermo Fisher Scientific
§ Vetter Pharma International
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Competitive Landscape
5. Biopharmaceutical Contract Manufacturing inNorth America
6. Biopharmaceutical Contract Manufacturing inEurope
7. Biopharmaceutical Contract Manufacturing inAsia Pacific And the Rest of The World
8. Biopharmaceutical Contract Manufacturing inAsia Pacific And the Rest of The World
9. Case Study: Outsourcing of Biosimilars
10. Case Study: Comparison of SmallMolecule and Large Molecule Drugs /Therapies
11. Case Study on In-House Manufacturing
12. Collaborations
13. Recent Developments
14. Capacity Analysis
15. Demand Analysis
16. Market Forecast
17. SWOT Analysis
18. Futureof The Biopharmaceutical CMO Market
19. Survey Analysis
20. Interview Transcripts
21. Appendix 1: List of Non-Industry Players
22. Appendix 1: List of Non-Industry Players
23. Appendix 3: List of Companies and Organizations
To purchase a copy, please visit https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
